An overview of translocation-related oncogenesis in the chronic myeloid leukaemias

Acta Haematologica
Barbara J Bain

Abstract

The demonstration of the BCR-ABL fusion gene in patients with chronic granulocytic leukaemia and t(9;22)(q34;q11) represents the first recognition, in a human neoplasm, of a translocation leading to formation of an oncogenic fusion gene. Since this initial observation, this leukaemogenic mechanism has been increasingly recognized in chronic myeloid leukaemias. The fusion gene has often incorporated part of a gene encoding a receptor or cytoplasmic tyrosine kinase, particularly ABL, PDGFRB and FGFR1. This contrasts with the frequent involvement of genes encoding transcription factors or other nuclear proteins in acute myeloid leukaemia. Nevertheless, genes encoding tyrosine kinases have also been implicated in some cases of acute leukaemia. With the exception of the BCR-ABL fusion gene in chronic granulocytic leukaemia, all these fusion genes are uncommon or rare among cases of chronic myeloid leukaemia. The molecular mechanisms underlying the great majority of cases of Philadelphia-negative chronic myeloid leukaemia remain to be discovered.

Citations

Jun 28, 2005·Leukemia Research·Maria Cristina RapanottiGiulio De Rossi
Jul 7, 2007·Leukemia & Lymphoma·Sook Young BaeIn Keun Choi
Dec 3, 2005·Leukemia & Lymphoma·Angela DispenzieriThomas E Witzig
May 27, 2004·Expert Review of Anticancer Therapy·Francesco Piazza, Gianpietro Semenzato
Jul 9, 2003·British Journal of Haematology·Barbara J Bain
May 6, 2016·Expert Opinion on Drug Metabolism & Toxicology·Gloria RavegniniPatrizia Hrelia
Jul 17, 2009·American Journal of Clinical Pathology·Juergen Thiele

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.